BLFS
BioLife Solutions, Inc.
NASDAQ · USHealthcareMedical - Instruments & Supplies
$29.09-0.21%
Price as of Jul 20, 2026
BLFS financials
BioLife Solutions, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $96.2M | $82.3M | $75.9M | $76.2M |
| Cost of revenue | $34.1M | $28.6M | $96.5M | $29.3M |
| Gross profit | $62.1M | $53.7M | $46.8M | $46.9M |
| Operating expenses | $62.9M | $60.8M | $117.6M | $52.8M |
| Operating income | -$1.1M | -$7.1M | -$23.4M | -$5.9M |
| Net income | -$12.1M | -$20.2M | -$66.4M | -$139.8M |
| EBITDA | $3.6M | $1.5M | -$45.2M | -$124.2M |
| Basic EPS | $-0.25 | $-0.44 | $-1.52 | $-3.29 |
| Diluted EPS | $-0.25 | $-0.44 | $-1.52 | $-3.29 |
| Balance sheet | ||||
| Cash & equivalents | $33.0M | $95.4M | $27.9M | $19.4M |
| Total assets | $405.9M | $399.5M | $412.7M | $450.2M |
| Total liabilities | $34.0M | $50.6M | $75.1M | $86.0M |
| Stockholders’ equity | $371.9M | $348.9M | $337.7M | $364.2M |
| Total debt | $17.9M | $30.2M | $33.8M | $43.7M |
| Net debt | -$15.1M | -$65.2M | $5.9M | $24.3M |
| Cash flow | ||||
| Operating cash flow | $20.1M | $8.4M | -$12.5M | -$8.5M |
| Capital expenditure | -$19.7M | -$3.2M | -$6.4M | -$10.4M |
| Free cash flow | $416.0K | $5.2M | -$18.9M | -$18.9M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |